Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

 


SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.


Trial Focus

Breast Cancer

Objective

         This is a clinical trial of everolimus that will be administered by mouth which is investigational and hormone treatment that will be administered by mouth and subcutaneous injection and is standard of care.

IRB Protocol #

13-1448

Trial Status

OPEN

Principle Investigator

ANTHONY ELIAS

Sponsor

SWOG

Contact

ABIGAIL CHER at -- or --

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 54 weeks. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with breast cancer.Eligibility criteria include but are not limited to 18 years or older with breast cancer.